Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORTISHOCK-P: Corticosteroids in Heart Failure Cardiogenic Shock
NCT07461961Phase 2Not yet recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Oct 2026
- Primary completion
- Feb 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in cardiogenic shock and heart failure (HF) comparing Methylprednisolone plus Standard of Care with Standard of Care (Control) (2 arms). Primary endpoint: Change in High-Sensitivity C-Reactive Protein Concentration. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
methylprednisolone injection
03
Conditions
cardiogenic shockheart failure (HF)
Beyond the preview
Go deeper on NCT07461961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07461961.